News | July 31, 2025
Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
It is intended for contrast enhancement in MRI scans
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
These medicines are essential in preventing RhD immunisation during pregnancy
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
